Equity · Healthcare
CERS
Cerus Corporation · NasdaqGM
The line runs $2.56 on 10 June through $2.58 on 4 September, on a scale from $2.0 to $3.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of CERS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 56 sessions over that window: $2.56 on 10 June 2026 through $2.58 on 4 September 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026
CERS insider trades
CERS has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 24 November 2025.
CERS reported financials
CERS reported revenue of $233.8M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$15.6M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
CERS earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
CERS institutional holders
9 of the 45 institutional funds we track reported a CERS position for the quarter ended 30 Jun 2026 — a combined $107.8M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
CERS fails-to-deliver
On 11 Aug 2026, 1,082 shares of CERS failed to deliver (about $3K) — the latest of 2 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data